The Hepatitis C Transplant Collaborative
Part of paid clinical trials in Dallas, Texas.
- Sponsor
- Baylor Research Institute
- Study ID
- NCT04493385
- Status
- Recruiting
Conditions
- Hepatitis C
- Transplant; Failure, Heart
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Study Details
In this study we seek to test the hypothesis that safety and clinical outcomes after cardiac transplantation utilizing HCV NAT+ donor organs as currently performed are acceptable.
Key Dates
- Start date
- Sep 16, 2019
- Status verified
- Jan 2026
- Primary completion
- Dec 31, 2030
- Completion
- Dec 31, 2030
Study Design
- Enrollment
- 500 participants (estimated)
Primary Outcome Measure
Number of donor HCV nucleic-acid testing positive (HCV NAT+) cardiac transplantation [ Time Frame: 6.5 years ]
Central Contacts
- Joost Felius, PhD214-818-8943
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Baylor Scott & White Health Research Institute | Dallas | Texas | 75246 |
Find similar trials in Dallas, TX
By research site
Related Studies
- Cardiopulmonary Stress Testing (CPET) AlloSure StudyRecruiting · Baylor Research Institute · Dallas, Texas
- EXCOR Active Driving System for the EXCOR Pediatric VAD IDE StudyEnrolling By Invitation · Berlin Heart, Inc · Los Angeles, California
- XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)Recruiting · XVIVO Perfusion · La Jolla, California
- Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIVPHASE1/PHASE2 · Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Los Angeles, California